Files in This Item:
|24_0435.pdf||733.83 kB||Adobe PDF||View/Open|
|Other Titles:||A CLINICAL EXPERIENCE W1TH THE USE OF FL-1039 (PIVMECILLINAM, PMPC) IN COMPLICATED INTRACTABLE URINARY TRACT INFECTION|
|Authors:||今井, 健一 |
|Author's alias:||Imabayashi, Kenichi|
|Abstract:||The clinical efficacy of Pivmecillinam (PMPC) on the complicated and intractable urinary tract infection was examined. At first, 200 mg of PMPC was administered orally for 7 days in 22 cases of out-patients with intractable urinary tract infections, of which some basic urological diseases were found in all cases, and even urethral indwelling catheters were found in 12 cases. Among them, 11 cases in which no significant effect was observed after the first 7 days administration of PMPC, more dose, 800 mg daily, was tried for subsequent 7 days. The clinical effect of PMPC was evaluated individually in three items, e.g. urinary finding, urinary micro-organism, and general condition, and final evaluation on the clinical efficacy was determined according to these clinical results. The excellent or good results were obtained in 9 cases (41 %) in the first item, 5 cases (23%) in the second item, and 8 cases (36%) in the third item, respectively. And the excellent or good results in final evaluation was obtained in 8 cases (36%). As to the side-effect, oppression feeling in the chest (1 cases) and light pain in the umbilical region (1 case) appeared after the first period of 200 mg of PMPC and the administration was stopped at that time. But these symptoms disappeared in a few days without any treatment after the suspension. After the second period of 800 mg of PMPC, nausea, anorexia, dizziness and dullness appeared in one case, but these symptoms diminished after the cessation of administration without any treatment. These three patients were thought to be rather nervous, and it was very difficult to prove that such complaints had actually resulted from the administration of PMPC.|
|Appears in Collections:||Vol.24 No.5|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.